Approximately 173,000 people in the United States are living with Hodgkin lymphoma, or are in remission. Less common than non-Hodgkin lymphoma, Hodgkin lymphoma (sometimes referred to as Hodgkin’s lymphoma) is a malignancy of B lymphocytes, an important cell in the immune system. This malignant B cell is known as the Reed-Sternberg cell.
1. What are the different types of Hodgkin lymphoma? There are two main types:
- Classical – This is the most common form, which can be broken down into four subtypes, including nodular sclerosing, mixed cellularity, lymphocyte depletion, and lymphocyte-rich.
- Nodular lymphocyte-predominant (NLPHL) – A rare form of Hodgkin lymphoma that is a slow-growing disease.
2. What are the risk factors for Hodgkin lymphoma? Age and gender can increase the chance of developing Hodgkin lymphoma. Other risk factors include:
- Being in young or late adulthood
- Being male
- Being exposed to the Epstein-Barr virus
- Having a first-degree relative (parent or sibling) with Hodgkin lymphoma
3. What are the symptoms of Hodgkin lymphoma? The most common signs of Hodgkin lymphoma are swollen (painless) lymph nodes in the neck, underarm, or groin, as well as fever, night sweats and weight loss. Other symptoms can include itchy skin, fatigue, cough or shortness of breath.
4. How do doctors diagnose Hodgkin lymphoma? Typically, the doctor will first conduct a physical exam to check for signs of health and any unusual lumps. The doctor will also check routine blood tests and perform scans, such as a CT scan or MRI.
Combination chemotherapy is used in both early and advanced stages of the disease, and depending on the stage or extent of disease, radiation therapy is added to parts of the body where there are sites of the disease.
Patients with a recurrence of the disease may be considered for a stem cell transplant. These transplants typically use the patient’s own stem cells.
Clinical trials of new chemotherapy combinations are also an option for patients in all stages of Hodgkin lymphoma, as well as patients with a recurrent form of the disease. Dana-Farber currently has several clinical trials open for Hodgkin lymphoma patients and the National Cancer Institute maintains a list of clinical trials at clinicaltrials.gov.